 |
      
|
|
|
|
|
|||||
|
|
January 20, 2004
To Support Its Synthetic Vaccine Program for About the Relationships
Neurochem has concluded this strategic alliance with the National Research Council of Canada and
Dr. Jennings to collaborate on the discovery and assessment of certain vaccine approaches in
animal models, and work towards the development of a specific vaccine using amyloid protein
fragment conjugates. This collaboration also includes the possibility of preclinical and
clinical development as well as future commercialization in the field of Aß-peptide-protein
conjugates. Through the licensing agreement with PRAECIS, Neurochem is expanding its pool of
intellectual property relating to specific Aß-derived peptide sequences. About the Vaccine
Neurochem's vaccine program targets a specific region of the Aß protein. This fragment, when made of
D amino acids conjugated to a carrier, generates an immune response where antibodies recognize only
the soluble form of the Aß protein. Preliminary experiments at Neurochem's laboratories have shown
that this type of conjugates protect mice as efficiently as the reported vaccine made with the
full Aß protein. One advantage of Neurochem's approach is that the antibodies do not recognize
plaques and therefore could help circumvent the risk of developing brain inflammation as was seen
with the full Aß protein vaccine. Neurochem's vaccine technology teamed with NRC's (Dr. Jennings)
know-how on vaccine technology is expected to lead to the development of a safe vaccine
protecting humans against Alzheimer's Disease. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's staged pipeline of proprietary, disease-modifying, oral products
addresses critical unmet medical needs. Fibrillex™, designated an orphan drug, is in a Phase
II/III clinical trial for AA amyloidosis. Alzhemed™ has completed a Phase II clinical trial for
the treatment of Alzheimer's Disease. Cerebril™ is in a Phase II trial for the prevention of
hemorrhagic stroke caused by cerebral amyloid angiopathy. For additional information on Neurochem,
please visit our website at: (www.neurochem.com).
All of the statements contained in this news release, other than statements of fact that are
independently verifiable at the date hereof, are forward-looking statements. Such statements, based
as they are on the current expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment
in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in
costs, and changes to the competitive environment due to consolidation or otherwise. Consequently,
actual future results may differ materially from the anticipated results expressed in the
forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
